Xenical Rx-To-OTC Switch Plans Underway
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline pays Roche $100 mil. for OTC marketing rights for the anti-obesity treatment. The two companies say they "have already begun work to develop an OTC orlistat formulation in the U.S."